Core Insights - Quantum BioPharma Ltd. is making significant advancements in its clinical pipeline, particularly with its FSD202 program targeting nociplastic pain in patients with Idiopathic Mast Cell Activation Syndrome (MCAS) and its Lucid-MS program for progressive Multiple Sclerosis [2][3] Clinical Development Milestones - The FSD202 program has received HREC approval for a Phase 2 clinical trial, enrolling 60 patients to assess pain reduction over 28 days [2] - The Lucid-MS program is expected to file an IND application with the U.S. FDA in Q4 2025, which would allow progression to Phase 2 trials [3] Strategic Business Developments - The subsidiary Celly Nutrition has rebranded to Unbuzzd Wellness Inc. and is preparing for a potential IPO to enhance capital for marketing its alcohol metabolism product [4] - Quantum BioPharma holds a 20.11% stake in Unbuzzd Wellness, positioning it to benefit from the subsidiary's growth [4] Financial Performance - For Q1 2025, Quantum BioPharma reported no revenues, with general and administrative expenses down 31% to $1.32 million, while R&D expenses rose to $1.65 million [6][7] - The company maintained cash and cash equivalents of $3.5 million as of March 31, 2025, ensuring liquidity through Q1 2027 [7] Pipeline Overview - The company's pipeline includes Lucid-MS for progressive Multiple Sclerosis, FSD202 for MCAS and inflammatory diseases, and unbuzzd™ for alcohol metabolism [8] Investment Strategy - Quantum BioPharma has diversified its treasury holdings towards Bitcoin, with total investments reaching $5 million [5] - The company plans to issue special dividends linked to potential litigation proceeds exceeding $700 million related to alleged stock manipulation [5]

Core Insights - Quantum BioPharma Ltd. has initiated a joint clinical study with Massachusetts General Hospital to validate a novel PET imaging technique for monitoring myelin integrity in multiple sclerosis (MS) patients [1][2] - The study utilizes the PET tracer [F]3F4AP, which has shown high sensitivity to demyelinated lesions and favorable pharmacokinetics in previous studies, indicating its potential as a biomarker for monitoring demyelination [1][3] - The new combined GE Signa PET-MR scanner at MGH enhances the imaging process by allowing simultaneous acquisition of PET and MRI signals, improving the accuracy of monitoring demyelination over time [2][3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation in MS [4] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [4] - Quantum BioPharma also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4]

Core Viewpoint - Quantum BioPharma Ltd. intends to declare a special dividend consisting of Contingent Value Rights (CVRs) to holders of its Class B Subordinate Voting Shares, reflecting the company's commitment to its shareholders [1][3]. Group 1: Special Dividend and CVRs - Each CVR will entitle holders to receive a pro rata portion of a minimum of 10% and a maximum of 50% of the net proceeds from the company's legal action against certain banks, seeking damages exceeding USD 700 million for alleged stock price manipulation [2][8]. - The exact payout percentage for the CVRs will be approved by the Board at a later date [2][3]. - The record date for the proposed special dividend has not yet been established, and further updates will be provided [3]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [4]. - The company’s lead compound, Lucid-MS, aims to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [4][8]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until total payments reach USD 250 million, after which the royalty will drop to 3% [4]. Group 3: Legal and Regulatory Considerations - The issuance of the CVRs is subject to necessary approvals, regulatory requirements, and finalization of tax, legal, and operational matters [3][8]. - There is no assurance that any proceeds from the litigation will be received or that the CVRs will result in any payment to holders [3][7].

Core Viewpoint - Quantum BioPharma Ltd. has purchased an additional USD $5,000,000 worth of Bitcoin and other cryptocurrencies as part of its strategic efforts to enhance shareholder returns and hedge against the dollar [1][2]. Group 1: Cryptocurrency Investment - The total amount of Bitcoin and other cryptocurrencies held by the company now stands at USD $5,000,000 [1]. - The company believes in the potential of cryptocurrencies to provide returns on investment for shareholders [2]. - Quantum BioPharma is set up to receive financing and conduct transactions in cryptocurrencies [2]. Group 2: Compliance and Custodianship - All cryptocurrency holdings are managed by a fully compliant custodian, ensuring adherence to financial and audit regulations [3]. - The company will continue to monitor market conditions and may adjust its cryptocurrency holdings as deemed appropriate [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [4]. - The company retains a 20.11% ownership stake in Celly Nutrition Corp., which includes a royalty agreement of 7% on sales from its product unbuzzd™ until total payments reach USD $250 million [4]. - Quantum BioPharma maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4].

Core Viewpoint - Quantum BioPharma Ltd. addresses misinformation regarding its name and potential reverse takeover with Unbuzzd Wellness Inc., clarifying that it has not changed its name and is not involved in any RTO transaction with Unbuzzd [1][2] Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [6] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. as of March 31, 2025, and has developed the product unbuzzd™, which aids in alcohol metabolism [6] Financial Agreements - Quantum BioPharma is the largest shareholder and debt holder of Unbuzzd Wellness Inc., receiving a 7% royalty on revenue until a total of $250 million is paid, after which the rate drops to 3% [3] - Quantum BioPharma has issued 200 million common shares to Unbuzzd Wellness Inc. as a license fee and holds an anti-dilution warrant to increase its stake to 25% [3] - A loan agreement was established where Quantum loaned Unbuzzd Wellness Inc. $1.3 million at a 10% annual interest rate, secured for three years [3] Leadership and Expertise - Unbuzzd Wellness Inc. is led by CEO John Duffy, who has a strong background in the beverage industry, and is supported by Gerry David, former CEO of Celsius Holdings, Inc. [4] Product Information - Unbuzzd is a scientifically-backed product that accelerates alcohol metabolism and reduces hangover symptoms, supported by clinical trials [9] - The product is available in various formats and aims to appeal to consumers looking for responsible drinking solutions [8][9] Debt Settlement - Quantum BioPharma has authorized a debt settlement totaling USD $20,930 with Class B Shares, expected to be completed in early June 2025 [5]

Core Viewpoint - Quantum BioPharma Ltd. announces the hiring of MNP LLP for PCAOB audits of Unbuzzd Wellness Inc. in preparation for a potential IPO, following the resignation of the previous auditor [1][2][3] Group 1: Company Developments - Unbuzzd Wellness Inc. has changed its name from Celly Nutrition Corp. effective May 23, 2025, with new CUSIP and ISIN numbers assigned [4] - The company is a non-trading but fully reporting public issuer focused on wellness and recovery supplements, specifically the unbuzzd beverage that aids in alcohol metabolism [8][9] - Unbuzzd has been scientifically validated through a double-blind, randomized, placebo-controlled clinical trial, demonstrating its effectiveness in accelerating alcohol metabolism and reducing hangover symptoms [9] Group 2: Financial and Audit Information - MNP LLP, a PCAOB-registered audit firm, has been engaged to conduct audits for Unbuzzd Wellness Inc. to ensure compliance and readiness for a possible IPO [2][3] - The previous auditor, Stern & Lovrics LLP, resigned at the company's request, and MNP was appointed based on the audit committee's recommendation [1][3] - There were no reservations or modified opinions in the previous auditor's reports, indicating a clean audit history for the most recent financial year [3] Group 3: Leadership and Strategic Direction - John Duffy, CEO of Unbuzzd Wellness Inc., emphasizes the importance of MNP's engagement in adhering to industry standards and preparing for the IPO [3] - Gerry David, Board Co-Chair, highlights the completion of PCAOB audits as a crucial step in raising capital and considering an IPO [3] - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to royalty payments from unbuzzd sales until a total of $250 million is reached [6]

Core Viewpoint - Quantum BioPharma Ltd. announces the hiring of MNP LLP for PCAOB audits of Unbuzzd Wellness Inc. in preparation for a potential IPO, following the resignation of the previous auditor [1][2][3] Group 1: Company Developments - Unbuzzd Wellness Inc. has engaged MNP LLP to conduct PCAOB audits effective May 20, 2025, to ensure compliance and readiness for a possible IPO [1][2] - The company has changed its name to Unbuzzd Wellness Inc. effective May 23, 2025, with new CUSIP and ISIN numbers assigned [4][5] - There were no reservations or modified opinions in the previous auditor's reports, indicating a clean audit history [3] Group 2: Product Information - Unbuzzd is a scientifically-proven beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms, appealing to a broad audience of alcohol consumers [8][9] - The product has been validated by a double-blind, randomized, placebo-controlled clinical trial, demonstrating its effectiveness in speeding up alcohol metabolism and reducing symptoms of intoxication [9] Group 3: Leadership Insights - John Duffy, CEO of Unbuzzd Wellness Inc., emphasizes the importance of MNP's engagement in adhering to industry standards and preparing for the IPO [3] - Gerry David, Board Co-Chair, highlights the completion of PCAOB audits as a crucial step in raising capital and considering an IPO [3] Group 4: Ownership and Financial Structure - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to 7% royalty payments from sales until reaching $250 million, after which the royalty rate will drop to 3% [6]

Core Viewpoint - Quantum BioPharma Ltd. has received approval for a Phase 2 clinical trial of FSD202, aimed at assessing its safety and efficacy in treating chronic widespread musculoskeletal nociplastic pain associated with idiopathic Mast Cell Activation Syndrome (MCAS) [1][4]. Group 1: Clinical Trial Details - The trial will enroll 60 patients with idiopathic MCAS, where participants will receive either FSD202 or a placebo twice daily for 56 days [1]. - The primary outcome will measure the decrease in average daily pain intensity from baseline to Day 28 [1]. - Secondary outcomes will also be evaluated during the trial [1]. Group 2: Drug Information - FSD202 contains ultra-micronized palmitoylethanolamide (PEA) and has potential applications for a variety of inflammatory diseases beyond MCAS [2]. - Chronic inflammatory diseases are a leading cause of death globally, with the World Health Organization identifying chronic disease as a significant health threat [2]. Group 3: Company Insights - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [4]. - The company retains a 20.11% ownership stake in Celly Nutrition, which is involved in the development of the OTC product unbuzzd™ [4]. - Quantum BioPharma has a royalty agreement with Celly Nutrition, receiving 7% of sales until total payments reach $250 million, after which the royalty rate will drop to 3% indefinitely [4].

Core Viewpoint - Quantum BioPharma Ltd. has partnered with BitGo Trust Company to manage and store its cryptocurrency assets, including Bitcoin, Solana, XRP, and DOGE coin, enhancing its security and compliance as a public company [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [3]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis [3]. - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition Corp., which markets the product unbuzzd™, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty will decrease to 3% [3]. Partnership with BitGo - BitGo will provide institutional-grade custody services, including multi-signature wallets and 100% cold storage technology, to protect Quantum's cryptocurrency assets from theft and unauthorized access [2]. - The partnership aligns with Quantum's priorities for security and compliance as it expands its engagement with cryptocurrency assets [2][3]. Industry Context - The collaboration with BitGo reflects a broader trend where institutions like Quantum are shaping the future of digital finance, emphasizing the need for secure and compliant infrastructure [3][5]. - BitGo is recognized as a leading provider of digital asset solutions, serving thousands of institutions and handling a significant portion of Bitcoin network transactions [5].

Core Insights - Quantum BioPharma Ltd. has signed an agreement with a global pharmaceutical contract research organization to prepare an IND application package for Lucid-21-302 (Lucid-MS) with the US FDA, aiming to initiate a Phase 2 trial for multiple sclerosis (MS) [1][3] - Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound designed to prevent demyelination, a key factor in MS and other neurodegenerative diseases [2] - The company plans to submit the IND application to the FDA in Q4 2025, marking a significant step towards advancing its treatment for MS [3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, that has shown potential in preclinical models [4] - The company retains a 20.11% ownership stake in Celly Nutrition Corp., which is involved in the marketing of unbuzzd™, and has established a royalty agreement that includes 7% of sales until reaching $250 million, after which the royalty will drop to 3% [4] - Quantum BioPharma also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4]